Table 2.
Association of VDR polymorphisms between patients and control groups (healthy donors and adenomatous polyps) and between different patients’ stages (II/III and IV).
| SNP | Genotype | Patient No (%) | Healthy No (%) | Adenomatous Polyps No (%) | p-Value | Stage II/III No (%) | Stage IV No (%) | p-Value |
|---|---|---|---|---|---|---|---|---|
| TaqI | Wt (TT) | 125 (31.5) | 71 (71) | 24 (60.0) | <0.001 | 108 (51.9%) | 17 (9.0%) | <0.001 |
| Hetero (Tt) | 129 (32.5) | 26 (26.0) | 11 (27.5) | 75 (36.1%) | 54 (28.6%) | |||
| Homo (tt) | 143 (36.0) | 3 (3.0) | 5 (12.5) | 25 (12.0%) | 118 (62.4%) | |||
| ApaI | Wt (AA) | 145 (36.5) | 56 (56.0) | 22 (55.0) | <0.001 | 120 (57.7%) | 25 (13.2%) | <0.001 |
| Hetero (Aa) | 122 (30.7) | 40 (40.0) | 17 (42.5) | 74 (35.6%) | 48 (25.4%) | |||
| Homo (aa) | 130 (32.7) | 4 (4.0) | 1 (2.5) | 14 (6.7%) | 116 (61.4%) | |||
| FokI | Wt (FF) | 122 (30.7) | 55 (55.0) | 21 (52.5) | <0.001 | 98 (47.1%) | 24 (12.7%) | <0.001 |
| Hetero (Ff) | 147 (37.0) | 40 (40.0) | 16 (40.0) | 89 (42.8%) | 58 (30.7%) | |||
| Homo (ff) | 128 (32.2) | 5 (5.0) | 3 (7.5) | 21 (10.1%) | 107 (56.6%) | |||
| BsmI | Wt (BB) | 75 (18.9) | 55 (55.0) | 13 (32.5) | <0.001 | 55 (26.4%) | 20 (10.6%) | <0.001 |
| Hetero (Bb) | 191 (48.1) | 43 (43.0) | 24 (60.0) | 116 (55.8%) | 75 (39.7%) | |||
| Homo (bb) | 131 (33.0) | 2 (2.0) | 3 (7.5) | 37 (17.8%) | 94 (49.7%) |